Global Biosimulation Market

Global Biosimulation Market Size, Share, Growth Analysis, By Application(drug development, drug discovery), By End user(pharmaceutical and biotechnology companies, academic institutes and research laboratories) - Industry Forecast 2024-2031


Report ID: SQMIG35I2104 | Region: Global | Published Date: April, 2024
Pages: 219 | Tables: 64 | Figures: 75

Global Biosimulation Market Insights

Global Biosimulation Market size was valued at USD 2.81 billion in 2022 and is poised to grow from USD 3.28 billion in 2023 to USD 11.46 billion by 2031, growing at a CAGR of 16.90% during the forecast period (2024-2031).

Biosimulation is a technique that simulates biological processes using computer programmes. Biosimulation has numerous applications in drug discovery and development. It is a tool for prediction, and biosimulation is used to predict the future outcomes of current experiments related to the discovery and development of new drugs.

The drug discovery and development process is costly, and the failure of a drug molecule in the late stages of drug development results in a massive waste of time, money, and other resources. As a result, there is a need for a predictive tool that will aid in predicting the future outcomes of drug development through simulation of the biological processes involved.

The biosimulation market grew significantly during the COVID-19 pandemic, owing to the importance of this technology in the study of drug development and how it interacts with the human body. As a result, biosimulation was extremely useful during the development of the COVID-19 vaccine. For example, when COVID-19 was declared a pandemic, Certara, a biosimulation technology company, began offering its services to companies developing a vaccine. As a result, the use of biosimulation was increased during the pandemic, which fueled market growth.

US Biosimulation Market  is poised to grow at a sustainable CAGR for the next forecast year.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Biosimulation Market size was valued at USD 2.81 billion in 2022 and is poised to grow from USD 3.28 billion in 2023 to USD 11.46 billion by 2031, growing at a CAGR of 16.90% during the forecast period (2024-2031).

To gain a larger market share, key players used competitive sustainability strategies such as product development and geographical presence expansion. Market leaders are also more likely to address unmet needs and provide economic value through consistent product upgrades. 'Certara', 'Dassault Systèmes SE', 'Simulations Plus Inc.', 'Schrödinger Inc.', 'Physiomics Plc', 'Advanced Chemistry Development Inc.', 'In silico biosciences Inc.', 'Genedata AG', 'Evidera Inc.', 'Leadscope Inc.', 'Insilico Biotechnology AG', 'Rhenovia Pharma SAS', 'Entelos Inc.', 'Biocomputing Platforms Ltd.', 'Rosa & Co. LLC', 'Genedata AG', 'OpenEye Scientific Software Inc.', 'Nexelis', 'Compugen Ltd.', 'Chemical Computing Group ULC'

The increasing pressure to lower healthcare costs, rising demand for biosimilars due to their cost-effectiveness, rising prevalence of various diseases, rising number of off-patent drugs, positive results in ongoing clinical trials, and rising demand for biosimilars in various therapeutic applications such as rheumatoid arthritis and blood disorders are some of the main factors driving growth in the global biosimilars market.

One of the key trends driving market growth is the rising incidence of drug relapse cases due to drug resistance in diseases such as cancer, tuberculosis, and other bacterial infections.

In 2021, North America had a revenue share of more than 45.0%. This expansion is attributed to the presence of key players, increased healthcare digitization, and the rising prevalence of chronic health issues. Furthermore, the use of in-silico models during regulatory policy enforcement to ensure high patient safety and treatment standards is contributing to regional market growth. Geographically, North America will dominate the worldwide biosimulation technology market in the years to come as a result of technical improvements, market expansion for biologics and biosimilars, high healthcare spending, and the presence of numerous pharma and biotech firms. Additionally, the U.S. Food and Drug Administration (FDA) highly suggests using simulation methods in drug research and development, hence promoting the expansion of the North American biosimulation technology market. In the global market for biosimulation technology, Europe is the region with the quickest growth. High healthcare costs and an increase in R&D activities are the main causes of the fastest growth in the region.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Biosimulation Market

Product ID: SQMIG35I2104

$5,300
BUY NOW GET FREE SAMPLE